1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
63DB1EF02AC6A4C6F00258BF20037CA5A
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/insights/driving-pharma-launch-success-through-strategic-resourcing-investment?opendocument
18
19opendocument
2018.97.9.174
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25Main






Driving Pharma Launch Success Through Strategic Resourcing and Investment

CHAPEL HILL, N.C., Dec. 13, 2024/ -- In today's competitive biopharma landscape, organizations need to strategically allocate resources to various launch activities to meet shifting stakeholder demands and capture market share.

An effective product launch hinges on three key factors: strategic positioning, proactive stakeholder engagement, and well-timed resourcing of commercial and medical efforts.

What are the key investment benchmarks for a successful pharmaceutical product launch?

According to our study, funding for market access and HEOR tends to rise significantly 24 to 36 months post-launch. In contrast, spending on samples, sales force preparation, and launch meetings tends to decrease during the same timeframe.

The report, titled "Winning Necessary Resources for a Successful Product Launch," engaged 48 commercial leaders from 38 companies, leveraging data from 51 product launches to develop competitive budgets for launch and pre-launch activities, equipping you with the tools for a strong market entry.

The report’s focus areas include:

  • Industry investments for new pharmaceutical product launch from 3 years prior to launch, through launch year
  • Budget allocation to 12 key marketing, education and market access activities during and prior to launch
  • Investment timing for conducting 50+ activities
  • FTE allocated to key launch activities
  • Anticipated budget and activity trends
  • Top success factors

For a deeper dive, download the complimentary report summary here: https://www.best-in-class.com/rw422.htm

Pressed for time? A short video summary of the key insights is available to provide an overview of the report's main recommendations:

 


 

 

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.

For Media Inquiries:

Email: psingh@bestpracticesllc.com

Website: https://www.best-in-class.com